The National Institutes of Health (NIH) is today the main source of new drugs in this country – indeed the world, because America leads in the field. It has a critical importance to America’s health. Less well known is its huge, positive, economic impact.
It’s been five years in the making, yet a bill requiring online retailers to label the country of origin for merchandise remains a tough sell in Congress—even among the lawmakers who introduced it back in 2020.
It’s been a rough start to 2025 for Indian pharmaceutical giants. Four of India’s biggest generic drug producers issued product recalls in the last three months.
In 2024, China and India accounted for 57.6% of total U.S. pharmaceutical imports by weight, highlighting the potential risks associated with such reliance. Growing U.S. dependence on China and India for widely-used generic pharmaceutical products creates serious risks to national security and patient safety when drugs are in short supply, or ineffective.
For far too long, America has been at the mercy of foreign producers that routinely violate FDA safety regulations for life-saving medicines, generic drugs, and essential medical equipment.
Food imports into the U.S. are on the rise. The trend now is for agricultural commodity trade deficits, rather than surpluses, with key commodities like beef usually in a deficit. Despite the increase in food imports, the Food and Drug Administration conducted far fewer than the annual goal of 19,200 inspections, according to FDA data.
De minimis, a customs rule that allows for duty free shipment and minimal inspection if the overseas vendor claims the value is under $800, is a haven for contraband, whether it’s fake Nikes, childrens’ toys made of lead, or banned food products, Customs and Border Protect (CBP) admitted yet again.
Commerce Secretary Gina Raimondo was asked to impose anti-dumping and countervailing duties (AD/CVD) on Southeast Asian solar companies in a letter from the United Steelworkers Union (USW) on Aug. 27.
The de minimis problem is getting worse. Consider this article a “Summer 2024” update of how the de minimis catastrophe continues to escalate.
Drug shortages are becoming commonplace in the U.S. Data from a new pharmaceutical industry tracking firm, Qyobo, shows hundreds of drugs are still in short supply – some well over a year — and our dependence on imports grows, including from labs on the receiving end of lackluster FDA inspections.
